Company Short-Term Debts: promisneurosciences.com (PMN)

Graphic logo of promisneurosciences.com (PMN)

Critical capital expenditure amid a funding shortage leaves ProMIS Neurosciences (PMN) dependent on new infusions. The volume of short-term loans visualizes this financial burden, where the 0.00 indicator determines the magnitude of the metric. Risks are amplified by the complete outsourcing of molecule synthesis to third-party laboratories, while business success relies exclusively on the efficacy of therapies for Alzheimer's disease and ALS.

Company Short-Term Loans and Borrowings: ProMIS Neurosciences (PMN) for 06/27/2023 - 10/28/2026

PMN (ProMIS Neurosciences Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart ProMIS|PMN - Consensus Target
- market capitalization data:
Market Capitalization ProMIS Neurosciences, Inc.|PMN - Enterprise Value
- book capitalization data:
Accounting Value per Share ProMIS Neurosciences|PMN - Accounting Value of Company|Market Value to Book Value Ratio promisneurosciences.com|PMN - Total Business Assets
- debt and liquidity data:
Total Debt to Capital ProMIS Neurosciences|PMN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio ProMIS|PMN - Company Aggregate Debts|Debt to Book Capitalization Ratio ProMIS Neurosciences, Inc.|PMN - Company Long-Term Loans and Borrowings|Company Short-Term Debt ProMIS Neurosciences
Fundamental company valuation:PMN promisneurosciences.com
Finished products of ProMIS Neurosciences

Short-term debt aggregates all obligations with a maturity of up to one year, allowing an assessment of liquidity risk and working capital pressure through the company's short-term debt dynamics. The current value of 0.00 reflects the financial stability of ProMIS Neurosciences (PMN), which is critical for management as it allocates resources toward high-tech research in the field of toxic brain protein therapy.

Competitor analysis for ProMIS Neurosciences

JAZZ: Company Short-Term Debt|CYTK - Company Current Liabilities|PTCT: Company Short-Term Debts|Company Short-Term Debts Scholar Rock Inc.|CNTA - Company Current Liabilities|Company Short-Term Loans and Borrowings DYN|Company Short-Term Debt Edgewise Therapeutics, Inc. EWTX|Company Short-Term Indebtedness Rapport Therapeutics Inc (RAPP)|ALMS: Company Short-Term Debts|ZVRA - Short-Term Debt|Contineum Therapeutics, Inc. - Company Current Liabilities|LRMR: Company Short-Term Debts|Company Short-Term Debt capricor.com CAPR|TRDA (Entrada Therapeutics Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt PTHS (Channel)|Short-Term Debt MNOV|Company Short-Term Debt Serina Therapeutics, Inc. (SER)|Company Short-Term Debt BTAI (bioxceltherapeutics.com)|APUS: Company Short-Term Debt|Short-Term Debt AEON Biopharma Inc. AEON|Company Short-Term Debts NLSP|Bionomics Limited (BNOX) - Short-Term Indebtedness|Company Current Liabilities HUGE|RETA (reatapharma.com) - Short-Term Debt